Drug data last refreshed 6m ago · AI intelligence enriched Yesterday
ZINGO is an intradermal lidocaine delivery system approved in 2007 for rapid, needle-free local anesthesia. It delivers lidocaine hydrochloride monohydrate via a spring-powered microprojection array, designed to provide anesthesia in seconds. The product targets patients requiring quick topical anesthesia prior to needle procedures.
ZINGO is in peak commercial phase with stable market positioning; team size and hiring likely modest given mature product status.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Efficacy and Safety of Zingo in Chinese Children
Working on ZINGO offers exposure to a stable, niche procedural anesthesia market with loyal customer base and strong patent protection through 2035. Career growth depends more on commercial execution and account management than on pipeline innovation or clinical expansion.
Worked on ZINGO at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo